Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of the combination of erlotinib
hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with
metastatic kidney cancer.